Publications by authors named "Ramin Oskoui"

4 Publications

  • Page 1 of 1

Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents.

Med Hypotheses 2021 Jun 5;153:110622. Epub 2021 Jun 5.

Concerned Ontario Doctors, Toronto, ON, Canada. Electronic address:

The outbreak of COVID-19 from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world with tremendous morbidity and mortality in the elderly. In-hospital treatment addresses the multifaceted nature of the illness including initial viral replication, cytokine storm, and endothelial injury with thrombosis. We identified nine reports of early treatment outcomes in COVID-19 nursing home patients. Multi-drug therapy including hydroxychloroquine with one or more anti-infectives, corticosteroids, and antithrombotic anti-blood clotting agents can be extended to seniors in the nursing home setting without hospitalization. Data from nine studies found hydroxychloroquine-based multidrug regimens were associated with a statistically significant > 60% reduction in mortality. Going forward, we conclude that early empiric treatment for the elderly with COVID-19 in the nursing home setting (or similar congregated settings with elderly residents/patients e.g. LTF or ALF) has a reasonable probability of success and acceptable safety. This group remains our highest at-risk group and warrants acute treatment focus prior to symptoms worsening. Given the rapidity and severity of SARS-CoV-2 outbreaks in nursing homes, in-center treatment of acute COVID-19 patients is a reasonable strategy to reduce the risks of hospitalization and death. If elderly high-risk patients in such congregated nursing home type settings are allowed to worsen with no early treatment, they may be too sick and fragile to benefit from in-hospital therapeutics and are at risk for pulmonary failure, life-ending micro-thrombi of the lungs, kidneys etc. The issue is timing of therapeutics, and we argue that early treatment before hospitalization, is the right time and can potentially save lives, especially among our higher-risk elderly populations hit hardest by severe illness and death from COVID-19. We must reiterate, we are talking about 'early' treatment before the disease is far along in the disease sequelae where the patient then needs hospitalization and aggressive interventions. We are referring to the initial days e.g. day one, post infection when symptoms emerge or there is strong clinical suspicion. This early therapeutic option deserves serious and urgent consideration by the medical establishment and respective decision-makers. Doctors must be allowed their clinical discretion in how they optimally treat their patients. Doctors must be brave and trust their skilled judgements and do all to save the lives of their patients. We therefore hypothesize that early outpatient ambulatory treatment, once initiated as soon as symptoms begin in high-risk positive persons, would significantly reduce hospitalizations and prevent deaths. Specifically, the provision of early multi-drug sequenced therapy with repurposed drugs will reduce hospitalization and death in elderly patients being cared for in long-term-care facilities. The most important implications of our hypothesis are: 1) hospitalizations and deaths would be reduced 2) transmission would be reduced due to the mitigation of symptoms and 3) recovery following infection and treatment provides for natural exposure immunity that is broad based, durable, and robust (helping towards natural immunity within the population). The end result is reduced strain on hospitals and systems that would allow for other non-COVID illnesses to receive care.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mehy.2021.110622DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178530PMC
June 2021

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).

Rev Cardiovasc Med 2020 12;21(4):517-530

Emergency Medicine, Phoenix, 85016, AZ, USA.

The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death. Prompt early initiation of sequenced multidrug therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and death. A multipronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combination intracellular anti-infective therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet agents/anticoagulants, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. Randomized trials of individual, novel oral therapies have not delivered tools for physicians to combat the pandemic in practice. No single therapeutic option thus far has been entirely effective and therefore a combination is required at this time. An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.31083/j.rcm.2020.04.264DOI Listing
December 2020

Early multidrug regimens in new potentially fatal medical problems.

Rev Cardiovasc Med 2020 Dec;21(4):507-508

Foxhall Cardiology, Washington, 20016, DC, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.31083/j.rcm.2020.04.270DOI Listing
December 2020

The effect of laterality on venous thromboembolism formation after peripherally inserted central catheter placement.

J Vasc Access 2012 Jan-Mar;13(1):91-5

Department of Internal Medicine, Georgetown University Hospital, Washington DC 20007, USA.

Purpose: The use of peripherally inserted central venous catheters (PICCs) has become widespread in hospital medicine. PICCs are preferentially placed on the right side due to anatomic ease of insertion into the superior vena cava. However, no data exists examining whether this practice is also protective against symptomatic venous thrombosis. The purpose of this study is to assess placement of right-sided versus left-sided PICCs and the resulting rates of venous thromboembolism (VTE) in a community teaching hospital.

Methods And Results: A retrospective analysis was performed of 798 sequential PICCs placed in our community teaching hospital in 2008. Indication for PICC placement, laterality of PICC placement, and signs and symptoms leading to ultrasound assessment were examined as well as the resulting VTE location. Six hundred and seventy two patients had a total of 798 PICCs placed over the course of the year, 568 of these were right-sided catheters, and 230 were left-sided catheters. Forty-nine of these patients required 68 Doppler ultrasounds within 30 days of PICC placement. Of these ultrasounds, 47 (8.27%) followed right-sided PICCs and 21 (9.13%) followed left-sided PICCs (OR 0.90, 95% CI 0.52-1.54). VTE events were documented in 1.23% of right-sided PICCs and 1.30% of left-sided PICCs (OR 0.94, 95% CI 0.24-3.68). The overall incidence of this complication was 1.25%. Mean time until discovery of the thrombus was 13.6 days.

Conclusions: Laterality of PICC placement is not significantly associated with symptomatic VTE formation. The overall rate of thrombosis in our study is comparable to that of previous studies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5301/jva.5000014DOI Listing
August 2012
-->